Page last updated: 2024-11-06

grepafloxacin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

grepafloxacin: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72474
CHEMBL ID583
CHEBI ID5543
SCHEMBL ID34155
MeSH IDM0203132

Synonyms (51)

Synonym
ccris 7284
3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-
3-quinolinecarboxylic acid, 1,4-dihydro-1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-
grepafloxacin [inn]
(+-)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
(+/-)-3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylic acid
119914-60-2
grepafloxacin
DB00365
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid
bdbm50117924
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methyl-piperazin-1-yl)-4-oxo-1,4,4a,8a-tetrahydro-quinoline-3-carboxylic acid (grepafloxacin)
CHEMBL583 ,
chebi:5543 ,
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxo-quino line-3-carboxylic acid
146863-02-7
AKOS016013941
pc-17116
grepafloxacin [inn:ban]
unii-l1m1u2hc31
l1m1u2hc31 ,
pc 17116
SCHEMBL34155
grepafloxacin [vandf]
(+/-)-1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid
grepafloxacin [who-dd]
3-quinolinecarboxylic acid, 1-cyclopropyl-6-fluoro-1,4-dihydro-5-methyl-7-(3-methyl-1-piperazinyl)-4-oxo-, (+/-)-
grepafloxacin [mi]
DTXSID2048321
1-cyclopropyl-6-fluoro-7-(3-methyl-1-piperazinyl)-5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
AIJTTZAVMXIJGM-UHFFFAOYSA-N
1-cyclopropyl-6-fluoro-7-(3-methyl-1-piperazinyl)5-methyl-1,4-dihydro-4-oxoquinoline-3-carboxylic acid
tomefloxacin; dl-grepafloxacin
SR-01000872592-1
sr-01000872592
HMS3713L05
rkl10071
FT-0703068
BCP23880
Q414846
opc17116
gtpl10818
1-cyclopropyl-6-fluoro-5-methyl-7-(3-methylpiperazin-1-yl)-4-oxo-quinoline-3-carboxylicacid
dl-grepafloxacin
EN300-19766404
CS-0017472
HY-A0147

Research Excerpts

Overview

Grepafloxacin (GPFX) is a new quinolone antibiotic (NQ) which is highly distributed to the lung and other tissues. It is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males.

ExcerptReferenceRelevance
"Grepafloxacin is a broad-spectrum fluoroquinolone derivative that has good tissue penetration. "( Priming by grepafloxacin on respiratory burst of human neutrophils: its possible mechanism.
Fujimoto, S; Hotta, K; Kanamori, Y; Kozawa, O; Matsuno, H; Niwa, M; Uematsu, T, 2002
)
2.15
"Grepafloxacin is an asymmetric fluoroquinolone derivative which possesses high tissue penetrability as well as strong, broad-spectrum antimicrobial activities. "( p38 MAPK associated with stereoselective priming by grepafloxacin on O2- production in neutrophils.
Fujimoto, S; Hirota, M; Hotta, K; Kanamori, Y; Kozawa, O; Kumada, M; Niwa, M, 2004
)
2.02
"Grepafloxacin (GPFX) is a new quinolone antibiotic (NQ) which is highly distributed to the lung and other tissues. "( Carrier-mediated uptake of grepafloxacin, a fluoroquinolone antibiotic, by the isolated rat lung cells.
Itose, M; Kato, Y; Miyamoto, G; Sasabe, H; Sugiyama, Y; Suzuki, T, 2005
)
2.07
"Grepafloxacin (OPC-17116) is a new once-daily fluoroquinolone antimicrobial agent which appears to have high tissue penetration and the wide spectrum of antimicrobial activity typical of this class of agents, but with improved activity against Gram-positive organisms, notably Streptococcus pneumoniae. "( Grepafloxacin.
Balfour, JA; Wagstaff, AJ, 1997
)
3.18
"Grepafloxacin is a well-tolerated alternative to cefixime for treatment of uncomplicated gonorrhea in males."( Comparison of single-dose oral grepafloxacin with cefixime for treatment of uncomplicated gonorrhea in men. The STD Study Group.
Bean, K; Hook, EW; Jones, RB; Maroli, AN; Martin, D; McCormack, WM, 1997
)
1.3
"Grepafloxacin is a fluoroquinolone antibiotic which is rapidly absorbed in healthy volunteers following oral dosing. "( Pharmacokinetics of grepafloxacin.
Efthymiopoulos, C, 1997
)
2.06
"Grepafloxacin is a new oral fluoroquinolone with potent activity against community acquired respiratory pathogens, including Streptococcuspneumoniae, and pharmacokinetic properties which allow once daily dosing. "( A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats.
Hasimoto, K; Itoh, N; Owen, K; Takizawa, T; Yamashita, S, 1999
)
2
"Grepafloxacin (GPFX) is a synthetic new quinolone antimicrobial agent that possesses an extensive tissue distribution and exhibits a strong antibacterial activity in vivo. "( Physiologically-based pharmacokinetic analysis of grepafloxacin.
Akiyama, H; Hattori, K; Iizasa, H; Matsunaga, N; Miyanmoto, G; Nakajima, Y; Nakashima, E; Sasabe, H; Shinsei, M, 2000
)
2

Effects

Grepafloxacin has a comparatively greater hepatobiliary transport than other quinolone antibiotics. It has a weak propensity for causing phototoxicity, similar to that of ciprofloxacins.

Grepafloxacin (GPFX) has a comparatively greater hepatobiliary transport than other quinolone antibiotics. It has a weak propensity for causing phototoxicity, similar to that of ciprofloxacins.

ExcerptReferenceRelevance
"Grepafloxacin (GPFX) has a comparatively greater hepatobiliary transport than other quinolone antibiotics. "( Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
Sasabe, H; Sugiyama, Y; Tsuji, A, 1998
)
1.97
"Grepafloxacin has a weak propensity for causing phototoxicity, similar to that of ciprofloxacin."( Grepafloxacin.
Balfour, JA; Wagstaff, AJ, 1997
)
2.46
"Grepafloxacin has an extremely broad spectrum of activity. "( Antibacterial activity of grepafloxacin.
Heisig, P; Wiedemann, B, 1997
)
2.04
"Grepafloxacin (GPFX) has a comparatively greater hepatobiliary transport than other quinolone antibiotics. "( Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
Sasabe, H; Sugiyama, Y; Tsuji, A, 1998
)
1.97
"Grepafloxacin has a weak propensity for causing phototoxicity, similar to that of ciprofloxacin."( Grepafloxacin.
Balfour, JA; Wagstaff, AJ, 1997
)
2.46
"Grepafloxacin has an extremely broad spectrum of activity. "( Antibacterial activity of grepafloxacin.
Heisig, P; Wiedemann, B, 1997
)
2.04
"Grepafloxacin has significantly increased adverse event rates, particularly gastrointestinal intolerance."( Safety of the new fluoroquinolones compared with ciprofloxacin.
Ball, P, 2000
)
1.03

Actions

Grepafloxacin did not cause convulsions in mice when administered in conjunction with the non-steroidal anti-inflammatory drug fenbufen. GrepafLoxacins exhibited a slower bactericidal effect against all the Gram-positive strains investigated.

ExcerptReferenceRelevance
"Grepafloxacin did not cause convulsions in mice when administered in conjunction with the non-steroidal anti-inflammatory drug fenbufen."( Safety profile of grepafloxacin compared with other fluoroquinolones.
Schwabe, R; Stahlmann, R, 1997
)
1.35
"Grepafloxacin exhibited a slower bactericidal effect against all the Gram-positive strains investigated in comparison with trovafloxacin in spite of a similar C(max)/MIC in the static experiments and a similar AUC/MIC ratio in the kinetic experiments."( Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
Cars, T; Lowdin, E; Odenholt, I, 2000
)
1.29

Toxicity

Grepafloxacin can be considered as a safe alternative for intravitreal injection for the treatment of intraocular infections. The most common adverse events with grepafl Oxacin 400 or 600 mg were gastrointestinal, such as nausea, vomiting, and diarrhea.

ExcerptReferenceRelevance
" Grepafloxacin was well tolerated, with the most frequently reported drug-related adverse events being taste perversion and nausea."( Efficacy and safety of grepafloxacin 600 mg daily for 10 days in patients with community-acquired pneumonia.
Breisch, SA; Maroli, AN; Swarz, H; Topkis, S,
)
1.35
" All treatments were well tolerated, with the most frequently reported drug-related adverse events being nausea, taste perversion, and headache."( Efficacy and safety of a 10-day course of 400 or 600 milligrams of grepafloxacin once daily for treatment of acute bacterial exacerbations of chronic bronchitis: comparison with a 10-day course of 500 milligrams of ciprofloxacin twice daily.
Breisch, S; Chodosh, S; Lakshminarayan, S; Swarz, H, 1998
)
0.54
" The most common adverse events observed for the 400 mg and 600 mg treatments during these studies were gastrointestinal reactions, such as nausea (11% and 15%, respectively), vomiting (1% and 6%) and diarrhoea (3% and 4%)."( Safety profile of grepafloxacin compared with other fluoroquinolones.
Schwabe, R; Stahlmann, R, 1997
)
0.63
" The most common adverse events with grepafloxacin 400 or 600 mg were gastrointestinal, such as nausea, vomiting, and diarrhea."( Grepafloxacin: a review of its safety profile based on clinical trials and postmarketing surveillance.
Elies, W; Lode, H; Vogel, F, 1999
)
2.02
" Ciprofloxacin is well tolerated; the incidence of adverse events is low and serious adverse events are rare."( Safety of the new fluoroquinolones compared with ciprofloxacin.
Ball, P, 2000
)
0.31
"Grepafloxacin can be considered as a safe alternative for intravitreal injection for the treatment of intraocular infections."( Histological toxicity of grepafloxacin after intravitreal injection.
Bregante, MA; Honrubia, FM; Larrosa, JM; Pablo, LE; Peréz-Oliván, S; Pinilla, I; Ramirez, MT; Solans, C,
)
1.88
" An understanding of structure-activity relationships (SARs) of chemicals can make a significant contribution to the identification of potential toxic effects early in the drug development process and aid in avoiding such problems."( Developing structure-activity relationships for the prediction of hepatotoxicity.
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ, 2010
)
0.36

Pharmacokinetics

The aim of the present investigation was to study and compare the killing activity of two new fluoroquinolone compounds. Grepafloxacin 400 mg was administered orally once daily for 7 days, and pharmacokinetic parameters were measured on days 1 and 7.

ExcerptReferenceRelevance
" The plasma terminal elimination half-life and urinary recovery remained unchanged."( Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.
Kanamaru, M; Kozawa, O; Matsuno, H; Nagashima, S; Niwa, M; Uematsu, T, 1996
)
0.52
" The half-life of grepafloxacin was about 12 hours after single doses and about 15 hours after repeat doses."( Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.
Bramer, SL; Efthymiopoulos, C; Maroli, A, 1997
)
0.95
" Child-Pugh scores and components of the scores showed no correlation with any pharmacokinetic variables."( Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction.
Bass, N; Bramer, SL; Efthymiopoulos, C; Flaherty, JF; Maroli, A; Somberg, K; Wolfe, E, 1997
)
1.74
" Population pharmacokinetic analysis was accomplished using iterative two-stage analysis."( Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
Amantea, MA; Chodosh, S; Collins, DA; Forrest, A; Schentag, JJ, 1997
)
0.56
" The aim of the present study was to investigate the different pharmacodynamic parameters of grepafloxacin in comparison with those of trovafloxacin."( Pharmacodynamic studies of trovafloxacin and grepafloxacin in vitro against Gram-positive and Gram-negative bacteria.
Cars, T; Lowdin, E; Odenholt, I, 2000
)
0.79
" Subsequently, the pharmacokinetics of GPFX were analyzed based on the physiological pharmacokinetic model."( Physiologically-based pharmacokinetic analysis of grepafloxacin.
Akiyama, H; Hattori, K; Iizasa, H; Matsunaga, N; Miyanmoto, G; Nakajima, Y; Nakashima, E; Sasabe, H; Shinsei, M, 2000
)
0.56
"The aim of the present investigation was to study and compare the killing activity of two new fluoroquinolone compounds, moxifloxacin and grepafloxacin, and a new generation macrolide, clarithromycin, against three clinical isolates of Streptococcus pneumoniae (penicillin-susceptible, -intermediate and -resistant) and two Streptococcus pyogenes (erythromycin-susceptible and -resistant) strains by simulating their human pharmacokinetics in a pharmacodynamic model."( Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Esposito, S; Ianniello, F; Noviello, S, 2000
)
0.76

Bioavailability

The results of these studies indicate that neither food nor the elevation of gastric pH influence the absorption or bioavailability of grepafloxacin.

ExcerptReferenceRelevance
" The results of these studies indicate that neither food nor the elevation of gastric pH influence the absorption or bioavailability of grepafloxacin."( Effect of food and gastric pH on the bioavailability of grepafloxacin.
Bramer, SL; Efthymiopoulos, C; Maroli, A, 1997
)
0.75
"The purpose of this study was to clarify the contribution of P-glycoprotein to the bioavailability and intestinal secretion of grepafloxacin and levofloxacin in vivo."( Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo.
Inui, K; Saito, H; Yamaguchi, H; Yano, I, 2002
)
0.74
"Cisplatin-induced ARF differentially modulated the bioavailability and intestinal secretion of quinolones in rats."( Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
Inui, K; Saito, H; Yamaguchi, H; Yano, I, 2004
)
0.32

Dosage Studied

Grepafloxacin's once-daily dosing regimen may offer advantages in terms of patient compliance. Intravenous injection of the drug caused transient dysrhythmias in rabbits at a dosage of 10 mg/kg.

ExcerptRelevanceReference
" Our results indicate that a once- or twice-daily dosage of grepafloxacin should be adequate to treat systemic infections caused by most bacterial pathogens."( Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin.
Andrews, JM; Child, J; Wise, R, 1995
)
0.77
" These features, together with the excellent bactericidal activity of grepafloxacin, support the recommended dosage regimen of grepafloxacin for the treatment of respiratory tract infections and sexually transmitted diseases."( Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.
Bramer, SL; Efthymiopoulos, C; Maroli, A, 1997
)
0.85
" The study group included 76 patients (43 male, 33 female) between 23 and 81 years of age, who were part of a multicentre, randomized, double-blind, dose-response study."( Pharmacokinetics and pharmacodynamics of oral grepafloxacin in patients with acute bacterial exacerbations of chronic bronchitis.
Amantea, MA; Chodosh, S; Collins, DA; Forrest, A; Schentag, JJ, 1997
)
0.56
" Intravenous injection of grepafloxacin caused transient dysrhythmias in rabbits at a dosage of 10 mg/kg and ventricular tachycardia at 30 mg/kg iv."( Safety profile of grepafloxacin compared with other fluoroquinolones.
Schwabe, R; Stahlmann, R, 1997
)
0.93
" Grepafloxacin's once-daily dosing regimen may offer advantages in terms of patient compliance."( Daily oral grepafloxacin vs. twice daily oral doxycycline in the treatment of Chlamydia trachomatis endocervical infection.
Hook, EW; Jones, RB; Martin, DH; McCormack, WM, 1998
)
1.6
" Groups of eight male Sprague-Dawley rats received either control material or grepafloxacin, enoxacin, lomefloxacin, ofloxacin or ciprofloxacin at an oral dosage of 300 mg/kg/day for 4 consecutive weeks."( A comparative study of the repeat dose toxicity of grepafloxacin and a number of other fluoroquinolones in rats.
Hasimoto, K; Itoh, N; Owen, K; Takizawa, T; Yamashita, S, 1999
)
0.78
" The area under the inhibitory serum concentration-time curve over 24 h (AUIC(24)), peak serum concentration:MIC ratio (C(max):MIC) and the percentage of the dosing interval during which the serum concentration exceeded the MIC (%tau >MIC) were calculated and serum inhibitory titres (SITs) were determined."( Comparison of the abilities of grepafloxacin and clarithromycin to eradicate potential bacterial pathogens from the sputa of patients with chronic bronchitis: influence of pharmacokinetic and pharmacodynamic variables.
Ballow, CH; Forrest, A; Hyatt, JM; Peloquin, CA; Sands, MF; Schentag, JJ; Tran, JQ, 2000
)
0.59
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (3)

ClassDescription
quinolinesA class of aromatic heterocyclic compounds each of which contains a benzene ring ortho fused to carbons 2 and 3 of a pyridine ring.
quinolone antibioticAn organonitrogen heterocyclic antibiotic whose structure contains a quinolone or quinolone-related skeleton.
fluoroquinolone antibioticAn organonitrogen heterocyclic antibiotic containing a quinolone (or quinolone-like) moiety and which have a fluorine atom attached to the central ring system.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency0.36130.005612.367736.1254AID624032
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)60.97240.00091.901410.0000AID161281; AID161284; AID243151; AID243188; AID276169; AID408340; AID420668; AID51930; AID576612; AID755684
Canalicular multispecific organic anion transporter 1Rattus norvegicus (Norway rat)Ki1,890.00000.84004.968210.0000AID679810
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
ATP-dependent translocase ABCB1Homo sapiens (human)Km580.00000.01403.717210.0000AID680130
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
G2/M transition of mitotic cell cycleATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic metabolic processATP-dependent translocase ABCB1Homo sapiens (human)
response to xenobiotic stimulusATP-dependent translocase ABCB1Homo sapiens (human)
phospholipid translocationATP-dependent translocase ABCB1Homo sapiens (human)
terpenoid transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of response to osmotic stressATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
transepithelial transportATP-dependent translocase ABCB1Homo sapiens (human)
stem cell proliferationATP-dependent translocase ABCB1Homo sapiens (human)
ceramide translocationATP-dependent translocase ABCB1Homo sapiens (human)
export across plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
positive regulation of anion channel activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transportATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic detoxification by transmembrane export across the plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transport across blood-brain barrierATP-dependent translocase ABCB1Homo sapiens (human)
regulation of chloride transportATP-dependent translocase ABCB1Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
protein bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATP bindingATP-dependent translocase ABCB1Homo sapiens (human)
ABC-type xenobiotic transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
efflux transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ATP hydrolysis activityATP-dependent translocase ABCB1Homo sapiens (human)
transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
ubiquitin protein ligase bindingATP-dependent translocase ABCB1Homo sapiens (human)
ATPase-coupled transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
xenobiotic transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
carboxylic acid transmembrane transporter activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylcholine floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
phosphatidylethanolamine flippase activityATP-dependent translocase ABCB1Homo sapiens (human)
ceramide floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
floppase activityATP-dependent translocase ABCB1Homo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (10)

Processvia Protein(s)Taxonomy
cytoplasmATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
cell surfaceATP-dependent translocase ABCB1Homo sapiens (human)
membraneATP-dependent translocase ABCB1Homo sapiens (human)
apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
extracellular exosomeATP-dependent translocase ABCB1Homo sapiens (human)
external side of apical plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membraneATP-dependent translocase ABCB1Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (106)

Assay IDTitleYearJournalArticle
AID150908Antibacterial activity was determined against gram negative organism, Pseudomonas aeruginosa (UI-18)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1557304AUC in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID497759Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID230840MIC ratio measured as the mean MICs of gram-positive bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID198316Antibacterial activity was determined against gram positive organism, Streptococcus pyogenes (C203)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID498782Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene by agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID117665In vivo subcutaneous protective dose was determined in female charles river CD-1 mice infected with Streptococcus pneumoniae1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID588210Human drug-induced liver injury (DILI) modelling dataset from Ekins et al2010Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 38, Issue:12
A predictive ligand-based Bayesian model for human drug-induced liver injury.
AID1664939Antimalarial activity against CQ-resistant Plasmodium falciparum NF54-R assessed as inhibition of parasite growth2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity.
AID498780Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID683719Antimalarial activity against liver stages of Plasmodium falciparum NF54 in mouse after 72 to 120 hrs by immunofluorescence assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID1557286Antibacterial activity against Streptococcus pyogenes by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557305Half life in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557328Cardiotoxicity in human QTc prolongation2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1125568Antimalarial activity against blood stage form of Plasmodium falciparum assessed as incorporation of [3H]hypoxanthine after 72 hrs by liquid scintillation counting2014European journal of medicinal chemistry, Apr-22, Volume: 77Emergence of pyrido quinoxalines as new family of antimalarial agents.
AID680109TP_TRANSPORTER: increase in brain concentration in mdr1a/1b(-/-) mouse2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID1557332Toxicity in human assessed as hepatic eosinophilia effect2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID682162TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, GPFX: 2500 uM) in OCT2A-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID588209Literature-mined public compounds from Greene et al multi-species hepatotoxicity modelling dataset2010Chemical research in toxicology, Jul-19, Volume: 23, Issue:7
Developing structure-activity relationships for the prediction of hepatotoxicity.
AID682310TP_TRANSPORTER: inhibition of Carnitine uptake (Carnitine: 0.010? uM, GPFX: 500 uM) in OCTN2-expressing HEK293 cells1999The Journal of pharmacology and experimental therapeutics, Nov, Volume: 291, Issue:2
Na(+)-dependent carnitine transport by organic cation transporter (OCTN2): its pharmacological and toxicological relevance.
AID679810TP_TRANSPORTER: inhibition of DNP-SG uptake in bile canalicular membrane vesicles from SD rat1998The Journal of pharmacology and experimental therapeutics, Mar, Volume: 284, Issue:3
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
AID680124TP_TRANSPORTER: transepithelial transport (basal to apical) in MDR1-expressing LLC-PK1 cells2001The Journal of pharmacy and pharmacology, May, Volume: 53, Issue:5
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.
AID755684Inhibition of human ERG current by patch clamp assay2013Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13
The synergic modeling for the binding of fluoroquinolone antibiotics to the hERG potassium channel.
AID198174Antibacterial activity was determined against gram positive organism, Streptococcus pneumoniae (SV-1)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1557303Cmax in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557281Antibacterial activity against Klebsiella by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID498781Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes by agar dilution method2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID498785Antimicrobial activity against mild ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID161284Inhibitory activity against Potassium channel HERG2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
AID230838MIC ratio measured as the mean MICs of gram-negative bacteria1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1557288Antibacterial activity against Clostridium perfringens by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID683718Antimalarial activity against liver stages of Plasmodium yoelii yoelii 265 BY infected in mouse after 48 hrs by immunofluorescence assay2012Journal of medicinal chemistry, Feb-09, Volume: 55, Issue:3
Targeting the liver stage of malaria parasites: a yet unmet goal.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1557287Antibacterial activity against Enterococcus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557279Antibacterial activity against Escherichia coli by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID497758Apparent permeability across basolateral to apical side in human Calu3 cells2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID498786Antimicrobial activity against strong ciprofloxacin-resistant Streptococcus pyogenes at 10 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID625295Drug Induced Liver Injury Prediction System (DILIps) validation dataset; compound DILI positive/negative as observed in Pfizer data2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID680130TP_TRANSPORTER: transepithelial transport (basal to apical) in Caco-2 cells2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Secretory mechanisms of grepafloxacin and levofloxacin in the human intestinal cell line caco-2.
AID243188Inhibition of human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel) in open state2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID497761Apparent permeability across basolateral to apical side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID498787Antimicrobial activity against ciprofloxacin-susceptible Streptococcus pyogenes harboring Asp91/Asn mutation in parC gene at 10 ug by disk diffusion assay2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Prevalence and clonal characterization of Streptococcus pyogenes clinical isolates with reduced fluoroquinolone susceptibility in Spain.
AID200230Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (H228)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1557280Antibacterial activity against Pseudomonas aeruginosa by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1557283Antibacterial activity against Haemophilus influenzae with horse blood by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID1557284Antibacterial activity against Staphylococcus aureus by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID497757Apparent permeability across apical to basolateral side in human Calu3 cells2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID51930K+ channel blocking activity in Chinese hamster ovary cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID1557306Protein binding in human at 0.4 g, po2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID681512TP_TRANSPORTER: decrease in intracellular accumulation in HL60 and HL60/ADM cells2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Limited distribution of new quinolone antibacterial agents into brain caused by multiple efflux transporters at the blood-brain barrier.
AID63899Antibacterial activity against gram negative organism, Escherichia cloacae (MA2646)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID117653In vivo oral protective dose was determined in female charles river CD-1 mice infected with Streptococcus pneumoniae1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1557285Antibacterial activity against Streptococcus pneumoniae by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID200231Antibacterial activity was determined against gram positive organism, Staphylococcus aureus (UC76)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID64254Antibacterial activity was determined against gram negative organism, E. coli(vogel)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1557323Toxicity in human assessed as gastrointestinal effect2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID442254Antimalarial activity against Plasmodium falciparum 3D72009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID1557324Toxicity in human assessed as arthralgia effect2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID681991TP_TRANSPORTER: inhibition of TEA uptake (TEA: 5 uM, GPFX: 2500 uM) in OCT2-expressing HEK293 cells2002Journal of the American Society of Nephrology : JASN, Jul, Volume: 13, Issue:7
cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID678912TP_TRANSPORTER: increase in Doxorubicin intracellular accumulation (Doxorubicin: 5 uM, GPFX: 500 uM) in P388/ADR cells2002Clinical and experimental pharmacology & physiology, Mar, Volume: 29, Issue:3
Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
AID276169Inhibition of human ERG potassium channel in HEK293 cells by patch clamp assay2006Bioorganic & medicinal chemistry letters, Nov-01, Volume: 16, Issue:21
Inhibitory effect of carboxylic acid group on hERG binding.
AID1664938Antimalarial activity against CQ-sensitive Plasmodium falciparum 3D7 assessed as inhibition of parasite growth2020ACS medicinal chemistry letters, Jul-09, Volume: 11, Issue:7
Synthesis of Novel Ciprofloxacin-Based Hybrid Molecules toward Potent Antimalarial Activity.
AID679114TP_TRANSPORTER: transepithelial transport (basal to apical) of Grepafloxacin at a concentration of 5uM in LLC-GA5-COL150 cells2004Pharmaceutical research, Feb, Volume: 21, Issue:2
Effect of cisplatin-induced acute renal failure on bioavailability and intestinal secretion of quinolone antibacterial drugs in rats.
AID117652In vivo oral protective dose was determined in female charles river CD-1 mice infected with Escherichia coli (vogel)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID94123Antibacterial activity was determined against gram negative organism, K. pneumoniae (MGH-2)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1557282Antibacterial activity against Bacteroides fragilis by agar diffusion method2019MedChemComm, Oct-01, Volume: 10, Issue:10
Quinolone antibiotics.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID151373Antibacterial activity was determined against gram negative organism, Providencia rettgeri. (M1771)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID678919TP_TRANSPORTER: decrease in intestinal clearance in mdr1a(-/-) mouse2001The Journal of pharmacy and pharmacology, May, Volume: 53, Issue:5
Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID497760Apparent permeability across apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID678894TP_TRANSPORTER: uptake in bile canalicular membrane vesicles from EHBR rat1998The Journal of pharmacology and experimental therapeutics, Mar, Volume: 284, Issue:3
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID497756Distribution coefficient, log D of the compound2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID117664In vivo subcutaneous protective dose was determined in female charles river CD-1 mice infected with Escherichia coli (vogel)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID442255Antimalarial activity against Plasmodium falciparum NF542009Journal of medicinal chemistry, Dec-24, Volume: 52, Issue:24
Enhancement of the antimalarial activity of ciprofloxacin using a double prodrug/bioorganometallic approach.
AID54107Minimum inhibitory concentration required to inhibit DNA gyrase supercoiling.1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID226390Bacterial minimum inhibitory concentration2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
AID679486TP_TRANSPORTER: uptake in Xenopus laevis oocytes1998FEBS letters, Nov-06, Volume: 438, Issue:3
Functional characterization of the rat multispecific organic anion transporter OAT1 mediating basolateral uptake of anionic drugs in the kidney.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID497762Efflux ratio of apparent permeability across basolateral to apical side over apical to basolateral side in human Calu3 cells in presence of 3 uM PSC-833 P-gp inhibitor2010Antimicrobial agents and chemotherapy, Jan, Volume: 54, Issue:1
Relative contributions of active mediated transport and passive diffusion of fluoroquinolones with various lipophilicities in a Calu-3 lung epithelial cell model.
AID430965Antibacterial activity against Escherichia coli 1596 containing parC K84 mutant assessed as decrease in MIC by Etest relative to MIC for Escherichia coli 1608 containing gyrA mutant2007Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11
Contributions of the combined effects of topoisomerase mutations toward fluoroquinolone resistance in Escherichia coli.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID682031TP_TRANSPORTER: uptake in bile canalicular membrane vesicles from SD rat1998The Journal of pharmacology and experimental therapeutics, Mar, Volume: 284, Issue:3
Carrier-mediated mechanism for the biliary excretion of the quinolone antibiotic grepafloxacin and its glucuronide in rats.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID681459TP_TRANSPORTER: increase in biliary excretion by Doxorubicin, Cyclosporin A and Erythromycin in vivo Wistar rat2002Clinical and experimental pharmacology & physiology, Mar, Volume: 29, Issue:3
Possible involvement of P-glycoprotein in the biliary excretion of grepafloxacin.
AID198020Antibacterial activity was determined against gram positive organism, Streptococcus faecalis (MGH-2)1991Journal of medicinal chemistry, Mar, Volume: 34, Issue:3
Synthesis and biological activity of 5-alkyl-1,7,8-trisubstituted-6-fluoroquinoline-3-carboxylic acids.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (193)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's92 (47.67)18.2507
2000's85 (44.04)29.6817
2010's15 (7.77)24.3611
2020's1 (0.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 28.44

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index28.44 (24.57)
Research Supply Index5.40 (2.92)
Research Growth Index4.17 (4.65)
Search Engine Demand Index39.34 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (28.44)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials21 (10.55%)5.53%
Reviews16 (8.04%)6.00%
Case Studies1 (0.50%)4.05%
Observational0 (0.00%)0.25%
Other161 (80.90%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Prospective Randomized Study to Compare Clinical Outcomes in Patients With Osteomyelitis Treated With Intravenous Antibiotics Versus Intravenous Antibiotics With an Early Switch to Oral Antibiotics [NCT02099240]Early Phase 111 participants (Actual)Interventional2014-03-06Terminated(stopped due to Not enough patient enrollment and lack of staffing)
[information is prepared from clinicaltrials.gov, extracted Sep-2024]